Nontuberculous Mycobacterial is a ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water.Common causative organisms of pulmonary infection are the slowly growing mycobacteria, M. avium complex (MAC) and M. kansasii and the rapidly growing mycobacteria, including M. abscessus complex.
Although more than 170 NTM species are present in various environmental niches, only a handful, primarily Mycobacterium avium complex and M. abscessus, have been implicated in pulmonary disease. NTM lung disease often affects elderly people with chronic lung disease and may be a manifestation of a complex genetic disorder determined by interactions among multiple genes, as well as environmental exposures.
Get Detailed Information about Nontuberculous Mycobacterial Market Share
Through DelveInsight’s Analysis, it can be observed that
moderate NTM infections cases are far higher in number than mild and severe
cases. It can also be observed that in Japan even though mild cases of NTM are
greater than moderate cases, still the combined cases of moderate cases of NTM
infections far outstrips the cases of mild NTM infections in 7MM (US, EU5, and Japan).
Since long, NTM infections have no proper cure, but
researchers are actively engaged in finding the cure through research on
antibacterial drugs. The American Thoracic Society (ATS) and Infectious Disease
Society of America (IDSA) recommends a standard NTM lung disease treatment with
antibiotic medications. One hope has risen with the approval of Arikayce in the
US. Generally, NTM infections patients are provided with antibiotics such as
azithromycin, ciprofloxacin, minocycline, cefoxitin, and imipenem.
Read more for in-depth information about Nontuberculous Mycobacterial Market Size
Comments
Post a Comment